Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Nothwehr, Steven F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Xia, Yi; Jeffrey Medeiros, L; Young, Ken H (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 1865:58-71
Xu-Monette, Zijun Y; Zhang, Shanxiang; Li, Xin et al. (2016) p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY) 8:345-65
Kanagal-Shamanna, Rashmi; Xu-Monette, Zijun Y; Miranda, Roberto N et al. (2016) Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology 68:482-91
Cao, Xin; Medeiros, L Jeffrey; Xia, Yi et al. (2016) Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 57:1104-13
Zhang, Xing-Ding; Baladandayuthapani, Veerabhadran; Lin, Heather et al. (2016) Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29:639-52
Zhou, Liang; Chen, Shuang; Zhang, Yu et al. (2016) The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127:2219-30
Ye, Qing; Xu-Monette, Zijun Y; Tzankov, Alexandar et al. (2016) Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 7:2401-16
Tang, Jinle; Li, Jialu; Zhu, Xuejun et al. (2016) Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 7:34070-83
Shah, Jatin J; Jakubowiak, Andrzej J; O'Connor, Owen A et al. (2016) Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res 22:34-43
de Winde, Charlotte M; Veenbergen, Sharon; Young, Ken H et al. (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest 126:653-66

Showing the most recent 10 out of 169 publications